Tesamorelin vs ipamorelin: what the evidence actually shows

Last updated 2026-07-25

What is the difference between tesamorelin and ipamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on the pituitary and stimulates the body's own pulsatile release of growth hormone, which in turn raises IGF-1 ^[1]. It's sold under the brand name Egrifta (and the newer autoinjector formulation Egrifta SV), and it carries FDA approval for a specific condition: reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy [10, 20]. Ipamorelin is a different class of molecule entirely: a growth hormone secretagogue that acts on the ghrelin receptor rather than the GHRH receptor. It was originally developed decades ago as a candidate GH-releasing drug, but it never completed development into an approved product. There is no ipamorelin listed in the FDA's Drugs@FDA database, and no phase 3 randomized controlled trial establishing its efficacy or safety in humans for fat loss or any other indication. The practical difference for a reader comparing the two is simple. One has a regulatory file with real human outcome data attached to a named condition. The other is a compound you'd get compounded or shipped as a research chemical, resting on receptor pharmacology and small mechanistic studies rather than outcome trials. A 2026 review on injectable peptide use in sports medicine put it plainly: most peptides used off-label in this space, ipamorelin included, lack the randomized trial evidence that supports an approved drug like tesamorelin [2, per Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians, PMID 41476424].

Is tesamorelin FDA-approved and is ipamorelin FDA-approved?

Yes and no, cleanly. Tesamorelin is FDA-approved, sold as Egrifta and Egrifta SV, for one specific use: reducing excess abdominal visceral fat in HIV patients with lipodystrophy ^[2]. That approval came out of two pooled multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data, published in the Journal of Clinical Endocrinology and Metabolism ^[3]. Ipamorelin has no FDA approval for any indication. It doesn't appear in the Drugs@FDA database of approved drug products. It also isn't on the FDA's 503A bulk drug substances list for human drug compounding, which matters because that list determines whether a compounding pharmacy can legally use a substance in a compounded human drug preparation under section 503A of the FD&C Act [11, 6]. The FDA maintains a separate list of substances nominated for 503A compounding that are still under evaluation, and unapproved GH secretagogues have moved on and off that nomination list over the years without landing on the final approved bulks list ^[4]. This is not a small technicality. FDA approval means a sponsor ran controlled trials, submitted safety and efficacy data, and got a specific labeled indication reviewed by regulators. Ipamorelin has never gone through that process for any use in the United States.

What does the clinical trial evidence show for each?

Tesamorelin's evidence base is unusually solid for a peptide drug. The pooled phase 3 analysis, covering two double-blind, placebo-controlled multicenter trials with extension data, found that tesamorelin significantly reduced visceral adipose tissue (VAT) compared with placebo in HIV patients with excess abdominal fat, with the effect sustained through extension periods ^[3]. A separate trial found that VAT reduction with tesamorelin was associated with improved liver enzyme levels in the same population ^[5]. More recent tesamorelin work has extended into related questions. A randomized, double-blind, multicenter trial in The Lancet HIV assessed effects on non-alcoholic fatty liver disease markers in people with HIV . A 2021 study found tesamorelin improved fat quality (attenuation, a marker of tissue composition) independent of raw changes in fat quantity ^[6]. A 2024 study in AIDS looked specifically at efficacy and safety in people with HIV on modern integrase inhibitor regimens, addressing whether newer antiretroviral backbones change the drug's effect ^[7]. A 2026 meta-analysis pooled body composition, hepatic fat, and metabolic and safety outcomes across the tesamorelin trial base ^[8]. Ipamorelin's human evidence, by contrast, is thin. There is no published phase 3 randomized controlled trial of ipamorelin for fat loss, body composition, or any indication resembling what tesamorelin is approved for. What exists in the literature is largely older receptor pharmacology work and small early-phase studies from its original development period, not the kind of outcome trial base that supports an approved-drug comparison. Recent peptide-therapy review articles covering orthopaedic and sports medicine use group ipamorelin among peptides used off-label with limited controlled human data [1, 5].

How does dosing compare between tesamorelin and ipamorelin?

Tesamorelin has an FDA-reviewed, label-defined dose: 2 mg administered by subcutaneous injection once daily, reconstituted from lyophilized powder. That dose came out of the phase 3 program and has documented pharmacokinetics; a 2015 population pharmacokinetic analysis modeled tesamorelin exposure across HIV-infected patients and healthy subjects to characterize absorption and clearance at the approved dose ^[9]. Ipamorelin has no FDA-reviewed dose. Whatever dosing protocol you see quoted online (commonly ranges like 200-300 mcg per injection, one to several times daily) comes from compounding pharmacy convention, anecdotal use, or extrapolation from other GH secretagogues, not from a regulator-reviewed dose-finding program. There's no dose established by controlled human trials the way there is for tesamorelin. For a reader trying to decide what to actually use, this is the crux: with tesamorelin you're following a labeled dose backed by pharmacokinetic modeling in the population it's approved for ^[9]. With ipamorelin you're following a convention with no equivalent regulatory backing. See our tesamorelin safety guide for how that labeled dose connects to monitoring recommendations.

What is each drug approved to treat (and what's off-label)?

Tesamorelin's approved indication is narrow: reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^[2]. It is not FDA-approved for general fat loss, for anti-aging use, for athletic performance, or for GH support in people without HIV-associated lipodystrophy. Any use outside that specific population and indication is off-label, even though the drug itself is FDA-approved. That distinction gets lost constantly in marketing copy, so it's worth stating directly here. Ipamorelin has no approved indication at all, in any population, for any purpose. There is no on-label use to point to. Everything ipamorelin is used for is, by definition, outside any regulatory approval, because no approval exists. Growth hormone and GH secretagogues are prohibited substances in competitive sport under anti-doping rules, and there's active analytical work on detecting GHRH analogues and secretagogues in athlete testing programs ^[10]. If drug testing matters to you, read our guide on tesamorelin and athlete drug testing before starting either compound.

How do the safety profiles compare?

Tesamorelin's safety data comes from a real trial base, including a documented adverse event profile from the phase 3 program and extension studies ^[3]. Injection site reactions are the most common issue reported. Because tesamorelin raises IGF-1 through GH stimulation, monitoring for fluid retention, joint symptoms, and glucose changes is part of standard use, and it carries label warnings around fluid retention and interference with glucose metabolism consistent with what's known about GH-axis stimulation generally [12, 22]. Ipamorelin's safety profile in humans is not established through comparable trials. Because it acts through the ghrelin receptor rather than GHRH receptor, its mechanism differs from tesamorelin, and it's sometimes marketed as having a more selective GH-release profile with less effect on cortisol or prolactin than older secretagogues. That claim traces mostly to receptor-binding and small mechanistic studies, not to a safety database built from large controlled human trials. Recent peptide-safety reviews covering musculoskeletal and performance uses explicitly flag this evidence gap for unapproved secretagogues as a class [3, 5]. For a fuller breakdown of tesamorelin's known adverse effects and monitoring needs, see is tesamorelin safe.

Does tesamorelin or ipamorelin help with visceral fat specifically?

Tesamorelin has direct trial evidence for visceral fat reduction; that's the entire basis of its FDA approval [10, 20]. The phase 3 trials measured VAT by imaging and showed statistically significant reductions versus placebo in HIV patients with lipodystrophy, with the effect linked to secondary improvements like liver enzymes ^[5] and liver fat markers in NAFLD-focused follow-up work . Ipamorelin has no comparable VAT-specific trial data. Any claim that ipamorelin reduces visceral fat rests on the general logic that GH secretagogues raise GH and IGF-1, which theoretically shifts body composition, not on a trial that measured VAT in humans given ipamorelin and compared it to placebo. That's a meaningfully different evidence tier than what backs tesamorelin's approved indication. It's also worth being blunt that tesamorelin's approval is for a specific patient population, HIV-associated lipodystrophy, not for otherwise healthy adults wanting general fat loss. The trial evidence doesn't extend that far, and using it for that purpose is off-label.

How do costs and access compare?

Tesamorelin as Egrifta or Egrifta SV is a prescription drug, obtained through a licensed prescriber and pharmacy, with insurance coverage possible depending on plan and diagnosis. Cash prices for brand-name tesamorelin commonly run into the hundreds of dollars per month, and exact pricing varies by pharmacy, dose, and insurance status; check current pricing directly with your pharmacy or prescriber rather than relying on outdated online figures. Ipamorelin is typically sold through compounding pharmacies or as a research chemical, without insurance coverage, and pricing varies widely by supplier and purity claims with no standardized reference price. Because it isn't on the FDA's approved 503A bulk drug substance list, its legal compounding status is murkier than tesamorelin's, and sourcing quality varies enormously between suppliers with no regulatory floor guaranteeing purity or accurate labeling [11, 6, 7]. If cost is the deciding factor, the honest framing is that tesamorelin costs more but buys you a regulated supply chain and trial-backed dosing. Ipamorelin may look cheaper per vial but comes with sourcing risk that's hard to quantify.

Which one has more real-world data behind it?

Tesamorelin has more than a decade of published clinical literature: phase 3 trials ^[3], liver and NAFLD-focused follow-ups [19, 21], neurocognitive outcome research in HIV patients with abdominal obesity ^[11], inflammatory marker studies , post hoc subgroup analyses (including patients with and without dorsocervical fat pads) , and a 2026 meta-analysis pooling body composition and metabolic outcomes across the RCT base ^[8]. That's a real, cumulative evidence trail spanning multiple independent research groups and journals. Ipamorelin does not have an equivalent trail. Its literature footprint is dominated by receptor pharmacology, older development-era studies, and mentions within broader peptide-review articles rather than dedicated outcome trials [1, 2, 5]. That doesn't mean ipamorelin definitely doesn't work through its proposed mechanism; it means nobody has run the kind of trial that would let you say with confidence what it does to human body composition at a given dose over a given time. If you're the kind of person who wants a paper trail before you inject something long-term, that gap should matter to your decision.

What would a provider actually recommend?

For the approved indication, HIV-associated lipodystrophy with excess visceral fat, tesamorelin is the drug with a regulatory file, a labeled dose, and trial evidence to justify prescribing it. That's a straightforward call for a physician managing a patient who fits that diagnosis. For anyone outside that population chasing general fat loss, GH support, or anti-aging effects, the honest answer is that neither drug has strong approved-use evidence for that goal. Tesamorelin used off-label at least comes with real pharmacokinetic and safety data from its approved-population trials [18, 20], even if that data doesn't perfectly generalize to a different population. Ipamorelin used for the same goal comes with essentially no controlled human trial data at all. If you're going the tesamorelin route, working through a provider-reviewed process rather than an unregulated online seller matters, particularly given how much variability exists in peptide sourcing quality. Tesamorelin Co's provider-reviewed pathway connects patients to prescribers who evaluate the actual indication before dispensing, with fulfillment through a licensed pharmacy partner, rather than shipping product with no clinical oversight attached. For background on what that oversight actually covers, see is tesamorelin safe. And if competitive testing is part of your life, tesamorelin and athletes drug testing is worth reading before you start either compound.

Tesamorelin vs ipamorelin: side-by-side comparison

Frequently asked questions

Is ipamorelin FDA-approved like tesamorelin?

No. Tesamorelin is FDA-approved as Egrifta and Egrifta SV for HIV-associated lipodystrophy with excess visceral fat ^[10]. Ipamorelin has no FDA approval for any indication and doesn't appear in the Drugs@FDA approved products database, nor on the FDA's 503A bulk drug substances list used for legal compounding.

Which is better for visceral fat loss, tesamorelin or ipamorelin?

Tesamorelin has direct phase 3 trial evidence of visceral fat reduction in HIV-associated lipodystrophy, which is its approved indication [10, 20]. Ipamorelin has no comparable controlled human trial measuring visceral fat outcomes, so any visceral-fat claim for it rests on mechanism, not outcome data.

Can tesamorelin be used for general fat loss, more than HIV lipodystrophy?

Only off-label. The FDA approval covers reduction of excess visceral adipose tissue specifically in HIV patients with lipodystrophy ^[10]. Using it for general fat loss in people without that diagnosis is off-label prescribing; it may still be done clinically, but it isn't what the trial evidence directly supports.

Does ipamorelin have any published clinical trials in humans?

There is no published phase 3 randomized controlled trial of ipamorelin for fat loss or body composition. The available literature leans on receptor pharmacology and older development-era work, and recent peptide-therapy reviews group it among off-label compounds with limited controlled human data [1, 5].

How are tesamorelin and ipamorelin different mechanistically?

Tesamorelin is a GHRH analogue: it binds the GHRH receptor on the pituitary to stimulate pulsatile GH release ^[2]. Ipamorelin is a ghrelin receptor agonist, a different GH secretagogue class, marketed as more selective with less effect on cortisol and prolactin than older secretagogues, though that claim rests mainly on mechanistic rather than outcome trial data.

Is ipamorelin legal to buy and use?

Ipamorelin isn't FDA-approved and isn't on the FDA's final 503A bulk drug substances list for compounding ^[11], which affects whether pharmacies can legally compound it into a human drug preparation under 21 U.S.C. 353a ^[12]. It's commonly sold as a research chemical, a legal gray zone that carries real sourcing and quality risk.

What is the FDA-approved dose of tesamorelin?

Tesamorelin's label dose is 2 mg by subcutaneous injection once daily, the dose used in the phase 3 trials and characterized by a 2015 population pharmacokinetic analysis across HIV-infected patients and healthy subjects ^[18]. Ipamorelin has no equivalent FDA-reviewed dose.

Does tesamorelin help with liver fat or NAFLD in HIV patients?

Yes, there's dedicated trial evidence. A randomized, double-blind, multicenter trial published in The Lancet HIV assessed tesamorelin's effect on non-alcoholic fatty liver disease markers in people with HIV ^[21], and an earlier study linked visceral fat reduction from tesamorelin to improved liver enzyme levels ^[19].

Will ipamorelin or tesamorelin show up on an athlete drug test?

Growth hormone and GH secretagogues, including GHRH analogues, are prohibited in competitive sport, and analytical methods for detecting these compounds in athlete testing are an active research area ^[8]. See tesamorelin and athletes drug testing for the specifics before using either compound if you're tested.

Is tesamorelin safe long-term?

Tesamorelin's safety data comes from phase 3 trials with safety extension periods ^[20], with injection site reactions the most common issue and monitoring recommended for fluid retention and glucose changes given its GH-stimulating mechanism ^[22]. See is tesamorelin safe for a full breakdown of documented adverse effects.

Why does tesamorelin have so much more research than ipamorelin?

Tesamorelin went through FDA drug development, which requires sponsor-funded phase 3 trials before approval, generating a decade-plus of published follow-up research [17, 20]. Ipamorelin never completed that pathway to approval in the US, so it lacks the trial infrastructure and funding that produces that scale of published evidence.

Can I get tesamorelin or ipamorelin without a prescription?

Tesamorelin as Egrifta requires a prescription through a licensed provider and pharmacy. Ipamorelin is often sold without a prescription requirement through compounding pharmacies or research chemical sellers, which is part of why its sourcing quality and legal standing are less consistent than an FDA-approved drug's.

Sources

1. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians, The American Journal of Sports Medicine, 2026 (PMID 41476424): Most peptides used off-label in sports medicine, including GH secretagogues, lack the randomized controlled trial evidence base of an approved drug.
2. Tesamorelin, Nature Reviews Drug Discovery, 2011 (PMID 21283099): Tesamorelin is a synthetic GHRH analogue that stimulates pituitary GH release via the GHRH receptor.
3. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance, Sports Medicine, 2026 (PMID 41966639): Unapproved GH secretagogue peptides used for performance and body composition lack the safety database that comes from large controlled human trials.
4. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions, JAAOS Global Research & Reviews, 2026 (PMID 41490200): Off-label peptide compounds used in orthopaedic and sports settings, including secretagogues like ipamorelin, are grouped as having limited controlled human trial data compared to approved therapeutics.
5. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, AIDS, 2024 (PMID 38905488): Tesamorelin's efficacy and safety were assessed specifically in people with HIV on integrase inhibitor regimens.
6. FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (current list): FDA maintains a nomination list of bulk substances under evaluation for 503A compounding status, separate from the final approved bulks list.
7. Advances in the detection of growth hormone releasing hormone synthetic analogs, Drug Testing and Analysis, 2021 (PMID 34665524): Analytical methods for detecting GHRH synthetic analogues and GH secretagogues in athlete drug testing are an active area of research.
8. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity, The Journal of Infectious Diseases, 2025 (PMID 39813152): Tesamorelin's effects on neurocognitive outcomes were studied in people with HIV and abdominal obesity.
9. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy, Drugs, 2011 (PMID 21668043): Tesamorelin is FDA-approved specifically for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
10. 21 CFR 216.24, the 503B Bulks List (eCFR): Federal regulation defines which bulk drug substances are permitted for outsourcing facility compounding, establishing the regulatory bar that unapproved peptides like ipamorelin have not cleared.
11. 21 U.S.C. 353a, pharmacy compounding (Cornell Law): Section 503A of the FD&C Act governs conditions under which compounded human drug preparations are exempt from standard FDA approval requirements.
12. Tesamorelin improves fat quality independent of changes in fat quantity, AIDS, 2021 (PMID 33756511): Tesamorelin improved visceral fat tissue quality (attenuation) independent of raw changes in fat quantity.
13. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of RCTs, Obesity Research & Clinical Practice, 2026 (PMID 41545261): A 2026 meta-analysis pooled body composition, hepatic fat, metabolic, and safety outcomes across randomized controlled trials of tesamorelin.
14. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects, Clinical Pharmacokinetics, 2015 (PMID 25358450): A population pharmacokinetic model characterized tesamorelin absorption and clearance at its approved dose in HIV-infected patients and healthy subjects.
15. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV, AIDS, 2017 (PMID 28832410): Tesamorelin-induced visceral fat reduction was associated with improved liver enzyme levels in people with HIV.
16. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials, Journal of Clinical Endocrinology and Metabolism, 2010 (PMID 20554713): Pooled phase 3 double-blind placebo-controlled trials with safety extension data formed the basis for tesamorelin's FDA approval and visceral fat efficacy data.
17. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial, The Lancet HIV, 2019 (PMID 31611038): A randomized, double-blind, multicenter trial assessed tesamorelin's effect on NAFLD markers in people with HIV.
18. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy, The Annals of Pharmacotherapy, 2012 (PMID 22298602): Tesamorelin's known adverse effect profile includes fluid retention and effects related to GH-axis stimulation requiring clinical monitoring.
19. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III trial, Journal of Clinical and Translational Science, 2023 (PMID 36845310): A post hoc subgroup analysis of the phase 3 tesamorelin trial examined outcomes in patients with and without dorsocervical fat pads.
20. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat, AIDS, 2011 (PMID 21516030): Tesamorelin's effect on inflammatory markers was studied in relation to visceral adipose tissue reduction in HIV patients.